Protocol No
NRG-GY027
Principal Investigator
William Bradley
Phase
I
Summary
This study is being done to answer the following question:
Can we improve the treatment outcomes of your ovarian cancer by adding ipatasertib to the usual combination of chemotherapies (paclitaxel and carboplatin)?
We are doing this study because we want to test the safety of a drug called ipatasertib at different doses.
Description
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov